Dyne Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 5, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 5, 2024
DYN$17.92-3.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
| Year Ended December 31, | ||
|---|---|---|
| (in thousands) | 2023 | 2022 |
| Cash flows from operating activities: | ||
| Net loss | $(235,937) | $(168,099) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 19,972 | 15,178 |
| Depreciation and amortization expense | 1,673 | 1,683 |
| Amortization (accretion) of premium (discount) on marketable securities | (1,102) | 1,276 |
| Loss on sale of marketable securities | 23 | 34 |
| Non-cash lease expense | 788 | 1,662 |
| Loss on disposal of property and equipment | 118 | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 3,337 | (4,144) |
| Accounts payable and other liabilities | 22,970 | (1,235) |
| Net cash used in operating activities | (188,158) | (153,645) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (729) | (3,067) |
| Purchases of marketable securities | (44,262) | (121,176) |
| Maturities of marketable securities | 126,473 | 208,291 |
| Sales of marketable securities | 1,829 | 3,154 |
| Net cash provided by investing activities | 83,311 | 87,202 |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock in public offering, net of issuance costs | 52,369 | 36,861 |
| Proceeds from exercise of stock options | 1,953 | 529 |
| Net cash provided by financing activities | 54,322 | 37,390 |
| Net decrease in cash, cash equivalents and restricted cash | (50,525) | (29,053) |
| Cash, cash equivalents and restricted cash, beginning of year | 174,466 | 203,519 |
| Cash, cash equivalents and restricted cash, end of year | $123,941 | $174,466 |
| Supplemental disclosures of cash flow information: | ||
| Purchase of property and equipment in accounts payable | $12 | $85 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.